Current status and future perspectives of radiomics in hepatocellular carcinoma

Table 4 Summary of the studies that evaluated radiomics to predict survival in patients with hepatocellular cholangiocarcinoma

Ref.	Country	n	Imaging modality	Endpoint	Treatment type	Segmentation	ROI/VOI	No. of readers	Main results	Validation
Kiryu et al[77], 2017	Japan	122	CT	Survival	Hepatic resection	Manual, intra- and peritumoral	ROI	1	OS and DFS were significantly different between 2 rad score groups	None
Xu et al[39], 2019	China	Training: 350. Validation: 145	CT	Survival	Hepatic resection	Semiautomatic, intratumoral	VOI	3	AUC: 0.91 (training), 0.81 (validation)	Internal
Akai et al[78], 2018	Japan	127	CT	Survival	Hepatic resection	Manual, intratumoral	ROI	1	OS and DFS were significantly different between 2 rad score groups	None
Kim et al[80], 2018	South Korea	88	CT	Survival	TACE	Manual, intratumoral	ROI	1	Combined clinical and radiomics score was a better predictor of survival	None
Blanc-Durand et al[81], 2018	Switzerland	47	18F-FDG PET-CT	Survival	TARE	Semiautomatic, whole liver	VOI	N/A	PFS-Rad Score and OS-Rad Score were independent negative predictors	None
Petukhova-Greenstein et al[82], 2022	United States	65	MRI	Survival	RFA	Semiautomatic, intra- and peritumoral	VOI	2	OS was significantly different between 2 rad score groups	None
Zheng et al[79], 2018	China	Training: 212. Validation: 107	CT	Survival	Hepatic resection	Manual, intratumoral	ROI	2	AUC: 0.71 (training and validation)	Internal

AUC: Area under the curve; CT: Computed tomography; DFS: Disease-fee survival; MRI: Magnetic resonance imaging; OS: Overall survival; PFS: Progression-free survival; RFA: Radiofrequency ablation; ROI: Region of interest; TACE: Transarterial chemoembolization; TARE: Transarterial radioembolization; VOI: Volume of interest; PET: Positron emission tomography.